VectivBio Extraordinary General Meeting of Shareholders Approved All Proposals
26. Juni 2023 16:01 ET
|
VectivBio AG
BASEL, Switzerland, June 26, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational...
VectivBio Publishes Invitation to the Annual General Meeting
10. Mai 2023 08:59 ET
|
VectivBio AG
BASEL, Switzerland, May 10, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio Reports Full Year 2022 Financial Results and Provides Business Update
19. April 2023 07:05 ET
|
VectivBio AG
Continued Strong Progress and Momentum Across Multiple Programs with Key Upcoming Data Milestones Beginning Q2 2023 STARS Phase 3 Program of Apraglutide in Short Bowel Syndrome with Intestinal...
VectivBio to Report Full Year 2022 Financial Results and Provide Business Update on Wednesday, April 19, 2023
12. April 2023 08:00 ET
|
VectivBio AG
BASEL, Switzerland, April 12, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in Japan
13. März 2023 08:00 ET
|
VectivBio AG
BASEL, Switzerland, March 13, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio Announces Results of Extraordinary General Meeting
09. Dezember 2022 16:01 ET
|
VectivBio AG
BASEL, Switzerland, Dec. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio Publishes Invitation to the Extraordinary General Meeting of Shareholders
16. November 2022 07:30 ET
|
VectivBio AG
BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio to Present at the 2022 Jefferies London Healthcare Conference
09. November 2022 08:28 ET
|
VectivBio AG
BASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio Announces Completion of Enrollment for Colon-In-Continuity (CIC) Cohort of STARS Pivotal Phase 3 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF)
03. November 2022 07:01 ET
|
VectivBio AG
-Largest global Phase 3 study ever conducted in SBS-IF recruiting a total of 144 patients, stratified 50/50 for Stoma and CIC anatomical subtypes -First Phase 3 study to prospectively evaluate safety...
VectivBio Announces Closing of $125 Million Underwritten Offering of Ordinary Shares
18. Oktober 2022 08:30 ET
|
VectivBio AG
BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...